Traditional Chinese medicine composition for clearing lung and benefiting throat, pharmaceutical preparation and application

Abstract

A traditional Chinese medicine composition for clearing the lung and benefiting the throat, a pharmaceutical preparation and a use. The traditional Chinese medicine composition is made of the following traditional Chinese medicine raw materials: forsythia 20-40 parts, honeysuckle 20-40 parts, mulberry leaf 20-40 parts, radix scrophulariae 20-40 parts, ophiopogon 7-11 parts and licorice 4-8 parts. In the mouse animal model experiment, the traditional Chinese medicine composition described herein not only can alleviate the phenomenon of neutrophil infiltration in the lung alveolar lavage fluid caused by LPS, reduce the inflammatory response; also helps to improve the lung tissue pathological damage induced by LPS, maintain the alveolar structure integrity, inhibit pulmonary edema, down-regulate the level of inflammatory factors in the lung alveolar lavage fluid, inhibit the expression of inflammatory factors in the lung tissue, thereby preventing and treating acute lung injury caused by LPS.

Description

Technical Field

[0001] This article generally covers the field of traditional Chinese medicine, especially a traditional Chinese medicine composition, pharmaceutical preparation and use for clearing the lungs and relieving sore throat. Background Technology

[0002] Acute lung injury (ALI) is caused by various factors leading to increased alveolar and capillary permeability, resulting in alveolar and interstitial edema, and consequently, hypoxic respiratory distress and other common respiratory complications. Severe cases can develop into acute respiratory distress syndrome (ARDS). Although many treatment strategies have been developed for ALI, clinical treatment is primarily supportive, including respiratory support, extracorporeal life support, and pharmacological therapy. The mortality rate of ALI remains high. Currently, no safe and effective drugs for treating ALI have been identified clinically. There is an urgent need to develop traditional Chinese medicine compositions for the treatment of acute lung injury. Summary of the Invention

[0003] Based on the above background, this application provides a traditional Chinese medicine composition for clearing the lungs and relieving sore throat, wherein, by weight, the traditional Chinese medicine composition is made from the following traditional Chinese medicine raw materials: 20-40 parts of Forsythia suspensa, 20-40 parts of Lonicera japonica, 20-40 parts of Mulberry leaf, 20-40 parts of Scrophularia ningpoensis, 7-11 parts of Ophiopogon japonicus and 4-8 parts of Glycyrrhiza uralensis.

[0004] In another aspect, this application also provides a pharmaceutical preparation comprising the traditional Chinese medicine composition described herein or an extract thereof.

[0005] On the other hand, this application also provides the use of the traditional Chinese medicine composition or pharmaceutical preparation described herein in the preparation of a medicament for the treatment and / or prevention of acute lung injury.

[0006] In mouse animal model experiments, the traditional Chinese medicine composition described herein not only alleviated neutrophil infiltration in bronchoalveolar lavage fluid (BALF) induced by LPS and reduced the inflammatory response, but also helped improve LPS-induced lung tissue pathological damage, maintain alveolar structural integrity, inhibit pulmonary edema, downregulate the level of inflammatory factors in BLF, and inhibit the expression of inflammatory factors in lung tissue, thereby preventing and treating LPS-induced acute lung injury. This application can provide a scientific basis and a safe and effective therapeutic drug for the clinical treatment of acute lung injury. This application studied the pharmacological effects of the traditional Chinese medicine composition described herein on acute lung injury, finding that it can alleviate the condition, control symptoms, and reduce mortality, providing a scientific basis and an effective therapeutic drug for the clinical prevention and / or treatment of acute lung injury.

[0007] Other features and advantages of this application will be set forth in the following description, and will be apparent in part from the description, or may be learned by practicing the application. Other advantages of this application can be realized and obtained by means of the solutions described in the description and the accompanying drawings. Attached Figure Description

[0008] The accompanying drawings are used to provide an understanding of the technical solutions of this application and constitute a part of the specification. They are used together with the embodiments of this application to explain the technical solutions of this application and do not constitute a limitation on the technical solutions of this application.

[0009] Figure 1 HE staining observation of the lungs of mice in each group in Example 3 of this application (20×).

[0010] Figure 2 The infiltration of CD11b and Ly6G neutrophils in the bronchoalveolar lavage fluid of mice in each group in Example 4 of this application is shown.

[0011] Figure 3 The total number of lung exudate cells in the bronchoalveolar lavage fluid of each group of mice in Example 4 of this application is shown.

[0012] Figure 4 The number of neutrophils in the bronchoalveolar lavage fluid of mice in each group in Example 4 of this application is shown.

[0013] Figure 5 The expression levels of IL-6 in the bronchoalveolar lavage fluid of mice in each group in Example 5 of this application are shown.

[0014] Figure 6 The expression levels of TNF-α in the bronchoalveolar lavage fluid of mice in each group in Example 5 of this application are shown.

[0015] Figure 7 The expression levels of IL-1β in the bronchoalveolar lavage fluid of mice in each group in Example 5 of this application are shown.

[0016] Figure 8 The expression levels of IL-6 mRNA in the lung tissues of mice in each group in Example 5 of this application are shown.

[0017] Figure 9 The expression levels of TNF-α mRNA in the lung tissues of mice in each group in Example 5 of this application are shown.

[0018] Figure 10 The expression levels of IL-1β mRNA in the lung tissues of mice in each group in Example 5 of this application are shown. Detailed Implementation

[0019] Unless otherwise stated, the technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this application pertains. When a quantity, concentration, or other value or parameter is expressed as a range, preferred range, or preferred upper and lower numerical limits, it should be understood that this is equivalent to specifically disclosing any range by combining any pair of upper or preferred values ​​with any lower or preferred value, regardless of whether the range is specifically disclosed. Unless otherwise stated, the numerical ranges listed herein are intended to include the endpoints of the range and all integers and fractions (decimals) within that range.

[0020] When used with a numerical variable, the terms "about" or "approximately" usually mean that the value of the variable and all values ​​of the variable are within the experimental error (e.g., within a 95% confidence interval for the mean) or within ±10% of the specified value, or a wider range.

[0021] The expression "comprising," or similar expressions such as "including," "containing," and "having," is open-ended and does not exclude additional unlisted elements, steps, or components. The expression "consisting of," excludes any unspecified elements, steps, or components. The expression "substantially consisting of," limits the scope to the specified elements, steps, or components, plus optional elements, steps, or components that do not materially affect the essential and novel features of the claimed subject matter. It should be understood that the expression "comprising" encompasses both the expressions "substantially consisting of" and "consisting of."

[0022] The expression "at least one" or "one or more" indicates 1, 2, 3, 4, 5, 6, 7, 8, 9 or more kinds.

[0023] Since the outbreak of pneumonia caused by the novel coronavirus, traditional Chinese medicine (TCM) has been involved in the entire treatment process, making significant contributions to the prevention and treatment of the disease. TCM has many years of experience in preventing and treating epidemics, and is safe, effective, and readily available, effectively treating respiratory diseases. The TCM composition proposed in this application is developed from the classic formula Yinqiao San. Its formulation principle is as follows: honeysuckle is sweet and cold, clearing heat and detoxifying, and dispersing wind-heat; forsythia is bitter and cold, clearing heat and detoxifying, reducing swelling and dissipating nodules; mulberry leaf is sweet, bitter, and cold, dispersing wind-heat in the upper burner, and effectively clearing lung heat and moistening dryness in the lung meridians; honeysuckle, forsythia, and mulberry leaf are combined to dispel wind, clear heat and moisten the lungs; scrophularia is bitter and slightly cold, cooling blood, nourishing yin and reducing fire, detoxifying, relieving sore throat and dissipating nodules; combined with ophiopogon japonicus to nourish yin and clear the lungs, and licorice to clear heat and detoxify, relieve sore throat and pain, and harmonize the various herbs. The overall formula has the effects of dispelling wind and clearing the lungs, detoxifying and relieving sore throat, and is suitable for symptoms such as lung inflammation and damage, sore throat, swelling and pain, and hoarseness caused by exogenous wind-heat.

[0024] In one aspect, this application provides a traditional Chinese medicine composition for clearing the lungs and relieving sore throat, wherein, by weight, the traditional Chinese medicine composition comprises: 20-40 parts of Forsythia suspensa, 20-40 parts of Lonicera japonica, 20-40 parts of Mulberry leaf, 20-40 parts of Scrophularia ningpoensis, 7-11 parts of Ophiopogon japonicus and 4-8 parts of Glycyrrhiza uralensis.

[0025] In some embodiments, the traditional Chinese medicine composition is made from the following traditional Chinese medicine raw materials in parts by weight: 20-40 parts of Forsythia suspensa, 20-40 parts of Lonicera japonica, 20-40 parts of Mulberry leaf, 20-40 parts of Scrophularia ningpoensis, 7-11 parts of Ophiopogon japonicus, and 4-8 parts of Glycyrrhiza uralensis.

[0026] In some embodiments, the traditional Chinese medicine composition is made from the following traditional Chinese medicine raw materials in parts by weight: 25-35 parts of Forsythia suspensa, 25-35 parts of Lonicera japonica, 25-35 parts of Mulberry leaf, 25-35 parts of Scrophularia ningpoensis, 8-10 parts of Ophiopogon japonicus, and 5-7 parts of Glycyrrhiza uralensis.

[0027] In some embodiments, the traditional Chinese medicine composition is made from the following traditional Chinese medicine raw materials in parts by weight: 30 parts forsythia, 30 parts honeysuckle, 30 parts mulberry leaf, 30 parts scrophularia, 9 parts ophiopogon japonicus and 6 parts licorice.

[0028] In another aspect, this application also provides a pharmaceutical preparation comprising the traditional Chinese medicine composition described herein or an extract thereof.

[0029] In some embodiments, the extract is an aqueous or alcoholic extract of the traditional Chinese medicine composition described herein.

[0030] In some implementations, the pharmaceutical formulation also includes pharmaceutically acceptable excipients.

[0031] In some embodiments, the excipients are selected from one or more of pharmaceutically acceptable solvents, solubilizers, cosolvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, flavoring agents, preservatives, suspending agents, coating materials, integrators, penetration enhancers, pH adjusters, buffers, plasticizers, surfactants, thickeners, inclusion agents, humectants, flocculants and deflocculators, filter aids, release inhibitors, polymeric framework materials, and film-forming materials.

[0032] In some embodiments, the dosage form of the pharmaceutical preparation is tablets, capsules, powders, pills, granules, oral liquids, syrups, decoctions, suppositories, gels, sprays, or injections. In some embodiments, the dosage forms of the pharmaceutical preparations in this application include capsules, tablets, pills, liquids, powders, granules, fine granules, film-coated agents, pills, lozenges, sublingual tablets, gels, sublingual preparations, pastes, syrups, suspensions, elixirs, emulsions, coatings, ointments, plasters, mud dressings, transdermal preparations, lotions, inhalers, aerosols, injections, and suppositories.

[0033] In some implementations, the pharmaceutical preparation is administered orally, intravenously, intradermally, transdermally, intrathecally, intra-arterially, intraperitoneally, intranasally, intravaginally, intrarectally, intrabladderally, intratumorally, locally, intramuscularly, subcutaneously, via mucosa, by inhalation, injection, infusion, or any combination thereof.

[0034] On the other hand, this application also provides the use of the traditional Chinese medicine composition or pharmaceutical preparation described herein in the preparation of a medicament for the treatment and / or prevention of acute lung injury.

[0035] On the other hand, this application also provides a method for treating and / or preventing acute lung injury, the method comprising: administering to a subject the traditional Chinese medicine composition or the pharmaceutical preparation described herein.

[0036] In some implementations, the subjects are humans, rats, mice, cats, dogs, horses, sheep, cows, and monkeys. Illustrative examples of subjects in some implementations include primates, particularly humans; companion animals such as cats and dogs and similar animals; working animals such as horses, donkeys, and similar animals; livestock animals such as sheep, cattle, goats, pigs, and similar animals; laboratory test animals such as rabbits, mice, rats, guinea pigs, hamsters, and similar animals; and captive wild animals such as captive wild animals in zoos and wildlife parks, deer, dingoes, and similar animals. In some implementations, the subjects are humans.

[0037] This application experimentally investigated the protective effect of the traditional Chinese medicine composition described herein against lipopolysaccharide (LPS)-induced acute lung injury. The traditional Chinese medicine composition significantly improved LPS-induced pathological damage to lung tissue; and further confirmed that its pharmacological effect is achieved by alleviating LPS-induced neutrophil infiltration in bronchoalveolar lavage fluid, downregulating the level of pro-inflammatory factors in bronchoalveolar lavage fluid, and inhibiting the expression of inflammatory factors in lung tissue. Based on the above novel properties of the traditional Chinese medicine composition described herein, this application identifies its novel use in the preparation of drugs for the treatment and / or prevention of acute lung injury, which has good efficacy, few toxic side effects, and promising potential value.

[0038] This application describes several embodiments, but these descriptions are exemplary and not restrictive, and it will be apparent to those skilled in the art that many more embodiments and implementations are possible within the scope of the embodiments described herein. Although many possible combinations of features are shown in the accompanying drawings and discussed in the detailed description, many other combinations of the disclosed features are also possible. Unless specifically limited, any feature of any embodiment may be used in combination with any other feature in any other embodiment, or may replace any other feature in any other embodiment.

[0039] This application includes and contemplates combinations of features known to those skilled in the art. The embodiments and features disclosed in this application can also be combined with any conventional features to form a unique inventive scheme as defined by the claims. Any feature of any embodiment can also be combined with features from other inventive schemes to form another unique inventive scheme as defined by the claims. Therefore, it should be understood that any feature shown and / or discussed in this application can be implemented individually or in any suitable combination. Therefore, the embodiments are not limited except by the limitations imposed by the appended claims and their equivalents. Furthermore, various modifications and changes can be made within the scope of the appended claims.

[0040] Furthermore, in describing representative embodiments, the specification may have presented methods and / or processes as a specific sequence of steps. However, the method or process should not be limited to the specific order of steps described herein, to the extent that it does not depend on such a specific order. As will be understood by those skilled in the art, other sequences of steps are also possible. Therefore, the specific order of steps set forth in the specification should not be construed as a limitation of the claims. Moreover, the claims concerning the method and / or process should not be limited to the steps performed in the written order, and those skilled in the art will readily understand that these orders can be varied and still remain within the spirit and scope of the embodiments of this application.

[0041] Experimental methods in the following embodiments without specific conditions are generally determined according to national standards. Experimental materials in the following embodiments without specified sources are all commercially available raw materials. The equipment used in each step of the following embodiments is conventional equipment. If there is no corresponding national standard, then generally accepted international standards, conventional conditions, or conditions recommended by the manufacturer are followed. Unless otherwise defined or stated, all technical and scientific terms used in this application have the same meaning as those skilled in the art. Furthermore, any methods and materials similar or equivalent to those described herein may be applied to the methods of this application.

[0042] Example

[0043] The materials used in the embodiments are shown below:

[0044] 1. Reagents and materials

[0045] Positive control drugs: Dexamethasone (MCE, HY-14648), Jinhua Qinggan Granules;

[0046] Lipopolysaccharide (LPS) (Sigma, L2880), PBS (macgene, CC008), APC-anti-mouse CD11b antibody (BioLegend, 101212), PE-anti-mouse Ly6G antibody (BD Pharmingen, 551461), mouse TNF-α pre-coated ELISA kit, mouse IL-6 pre-coated ELISA kit, mouse IL-1β pre-coated ELISA kit (DAKEWE, 1217202, 1210602, 1210122), 0.9% NaCl injection.

[0047] 2. Laboratory animals

[0048] Healthy male C57BL / 6 mice (8 weeks old, weighing 20±2g) were purchased from Spiford Biotechnology Co., Ltd. All mice were placed in an environment with 12 hours of light / dark cycles (room temperature 25℃, humidity 50%) and had free access to food and water for 5 days of acclimatization feeding.

[0049] Example 1. Preparation of the drug

[0050] In the embodiments, the traditional Chinese medicine composition used herein is a granule form of the traditional Chinese medicine composition.

[0051] Preparation of the traditional Chinese medicine composition granules: The raw materials—Forsythia suspensa 30g, Lonicera japonica 30g, Morus alba leaf 30g, Scrophularia ningpoensis 30g, Ophiopogon japonicus 9g, and Glycyrrhiza uralensis 6g—were converted into granule formulations according to the Chinese Pharmacopoeia standard: Forsythia suspensa 9.1g, Lonicera japonica 10g, Morus alba leaf 7.5g, Scrophularia ningpoensis 20g, Ophiopogon japonicus 8.18g, and Glycyrrhiza uralensis 2g. The granules were then mixed to obtain the traditional Chinese medicine composition granules of this application.

[0052] In previous research, the traditional Chinese medicine composition of this application has been used clinically in adults. The maximum dosage for adults was found to be 56.78 g / day (based on the weight of the formulation granules and 135 g / day based on the weight of the raw material). Based on an adult weight of 70 kg, the equivalent dosage for mice is 7.3814 g / kg (based on the weight of the formulation granules and 17.55 g / day based on the weight of the raw material).

[0053] LPS solution (4 mg / kg): Weigh 8 mg of LPS powder and dissolve it in 5 mL of 0.9% NaCl injection to obtain an LPS solution of 1.6 mg / mL.

[0054] Low-dose (7.4g / kg) of traditional Chinese medicine composition granules: 1 times the clinical dose, weigh 3.7g of traditional Chinese medicine composition granules and dissolve them in 5mL of 0.9% NaCl injection, with each dose administered via gavage in a volume of 0.2mL.

[0055] High dose of traditional Chinese medicine composition granules (14.8g / kg): 2 times the clinical dose. Weigh 7.4g of traditional Chinese medicine composition granules and dissolve them in 5mL of 0.9% NaCl injection. The volume of each gavage is 0.2mL.

[0056] Positive control: Dexamethasone (5 mg / kg): Weigh 2.5 mg of dexamethasone and dissolve it in 5 mL of 0.9% NaCl injection solution. The intraperitoneal injection volume for each animal is 0.2 mL.

[0057] Jin Hua Qing Gan Granules (6g / kg): Weigh 3g of Jin Hua Qing Gan Granules and dissolve them in 5mL of 0.9% NaCl injection solution. The volume for each gavage is 0.2mL.

[0058] Example 2. Animal Experiment

[0059] In the embodiments of this application, the traditional Chinese medicine composition granules are also known as Qingfei Liyan Decoction (Q).

[0060] Mice were randomly divided into 7 groups: blank control (CON), blank control + Qingfei Liyan Decoction (CQ), LPS (LPS), LPS + Qingfei Liyan Decoction (7.4 g / kg) (QL), LPS + Qingfei Liyan Decoction (14.8 g / kg) (QH), LPS + Dexamethasone (5 mg / kg) (DEX), and LPS + Jinhua Qinggan Granules (6 g / kg) (JHQG). The CQ, QL, and QH groups were pre-administered Qingfei Liyan Decoction by gavage for 5 days, the JHQG group was pre-administered Jinhua Qinggan Granules by gavage for 5 days, the DEX group was intraperitoneally injected with dexamethasone for 5 days, and the CON and LPS groups were simultaneously administered an equal volume of physiological saline by gavage. Six hours after the last administration, mice were anesthetized by intraperitoneal injection of 1% sodium pentobarbital. The LPS, QL, QH, DEX, and JHQG groups received 50 μL of LPS (4 mg / kg) via tracheal infusion, while the CON and CQ groups received an equal volume of physiological saline via tracheal infusion. After the mice gradually recovered, the CQ, QL, and QH groups were administered Qingfei Liyan Decoction by gavage, the DEX group received dexamethasone via intraperitoneal injection, and the JHQG group received Jinhua Qinggan Granules by gavage. Twelve hours after treatment, the mice were euthanized, and lung tissue and bronchoalveolar lavage fluid were collected. The left lung tissue was fixed in 4% paraformaldehyde solution for 24 hours, dehydrated stepwise with alcohol, and then embedded in paraffin to form a wax block. After tissue trimming, sections were prepared to a thickness of 4-8 μm and stained with hematoxylin and eosin (HE). The right lung tissue was placed in cryovials for homogenization and then subjected to real-time quantitative qPCR.

[0061] After euthanasia, the thoracic cavity and trachea of ​​mice were exposed, the trachea was ligated, and the lungs were flushed three times with 1 mL of pre-chilled PBS to obtain bronchoalveolar lavage fluid (BALF). 10 μL of BALF was aspirated and counted using a cell counting chamber. The counted BALF was centrifuged at 4°C (1500 rpm, 10 min), and the cell-free supernatant was collected and stored at -80°C for analysis of inflammatory factors. 100 μL of pre-chilled PBS was added to the cell pellet to resuspend the cell particles, which were then used for flow cytometry analysis of neutrophil infiltration using APC-CD11b / PE-Ly6G. 2 μL of APC-CD11b and PE-Ly6G were added to the cell suspension, and the mixture was incubated at room temperature in the dark for 30 min, then centrifuged at 4°C (1200 rpm, 5 min), and the supernatant was discarded. After thorough washing with PBS, the sample was resuspended in 200 μL of 2% paraformaldehyde and placed at 4°C for analysis using a FACSCanto II flow cytometer (BD Biosciences, USA).

[0062] BALF supernatant was prepared for ELISA detection. ELISA kits were used to detect TNF-α, IL-6, and IL-1β levels, and standard curves were used to calculate the concentrations of inflammatory factors.

[0063] Total RNA was extracted from lung tissue using Trizol and reverse transcribed into complementary DNA (cDNA) using RT SuperMix according to the instructions. It was then amplified by SYBR qPCR and quantitative real-time PCR was performed using a Quantstudio 6Flex PCR analyzer.

[0064] Example 3. Comparison of HE staining of mouse lungs in different groups

[0065] Staining results are shown Figure 1 The LPS group showed alveolar structure disruption and alveolar wall thickening, leading to a large number of inflammatory cells infiltrating the bronchoalveolar lavage fluid, indicating successful establishment of an acute lung injury model. Compared with the ALI model group, the degree of lung injury in mice in the QL, QH, DEX, and JHQG groups was reduced to varying degrees. Histopathological analysis showed the protective effect of Qingfei Liyan Decoction.

[0066] Example 4. Analysis of neutrophil infiltration in bronchoalveolar lavage fluid of mice in each group

[0067] like Figure 2 , Figure 3 , Figure 4As shown, APC-CD11b and PE-Ly6G are markers of neutrophils. Flow cytometry detection of APC-CD11b and PE-Ly6G in BALF revealed a large number of CD11b+ and Ly6G+ neutrophils in the lungs after LPS treatment. The lack of significant difference between the CON and CQ groups confirms the safety of Qingfei Liyan Decoction in animals. Qingfei Liyan Decoction, dexamethasone, and Jinhua Qinggan Granules showed a certain inhibitory effect on LPS-induced neutrophil infiltration and pulmonary exudative cells (AECs).

[0068] Example 5. Comparison of bronchoalveolar lavage fluid and lung tissue inflammation in different groups of mice

[0069] The levels of pro-inflammatory factors IL-6, TNF-α, and IL-1β in BALF supernatant were detected using an enzyme-linked immunosorbent assay (ELISA) kit. Compared with the CON group, the LPS group showed a significant increase in the secretion of inflammatory mediators in BALF. Compared with the LPS group, the levels of inflammatory factors in the Qingfei Liyan Decoction treatment group, DEX group, and JHQG group were significantly decreased. Figures 5-7 ).according to Figures 8-10 Analysis revealed that all inflammatory cytokine mRNAs detected in the lung tissue of the LPS group were upregulated, while the treatment groups showed reduced expression of pro-inflammatory cytokine mRNAs in the lung tissue, especially at high doses of Qingfei Liyan Decoction. These results indicate that Qingfei Liyan Decoction can improve LPS-induced acute lung injury, reduce inflammatory cell infiltration, and decrease the secretion of inflammatory factors.

[0070] In summary, the traditional Chinese medicine composition of this application can alleviate the degree of lung injury caused by LPS, such as alveolar wall thickening and alveolar structure destruction, reduce neutrophil infiltration in BALF, and decrease the levels of inflammatory factors IL-6, TNF-α, and IL-1β in BALF, as well as reduce the expression of pro-inflammatory factors IL-6, TNF-α, and IL-1β mRNA in lung tissue. Furthermore, the inflammatory markers in the QH group were superior to those in the JHQG group. Jin Hua Qing Gan granules have played an important role in the treatment of pneumonia caused by novel coronavirus infection, demonstrating good clinical efficacy. Therefore, the traditional Chinese medicine composition of this application can also be further developed into a clinical drug for the prevention and / or treatment of lung diseases. The examples of this application have confirmed that the traditional Chinese medicine composition of this application has good preventive and / or therapeutic effects on acute lung injury.

Claims

1. A traditional Chinese medicine composition for treating and / or preventing acute lung injury, wherein, The traditional Chinese medicine composition is made from the following raw materials by weight: 20-40 parts of Forsythia suspensa, 20-40 parts of Lonicera japonica, 20-40 parts of Mulberry leaf, 20-40 parts of Scrophularia ningpoensis, 7-11 parts of Ophiopogon japonicus, and 4-8 parts of Glycyrrhiza uralensis.

2. The traditional Chinese medicine composition according to claim 1, wherein, The traditional Chinese medicine composition is made from the following traditional Chinese medicine raw materials in parts by weight: 25-35 parts of Forsythia suspensa, 25-35 parts of Lonicera japonica, 25-35 parts of Mulberry leaf, 25-35 parts of Scrophularia ningpoensis, 8-10 parts of Ophiopogon japonicus, and 5-7 parts of Glycyrrhiza uralensis.

3. The traditional Chinese medicine composition according to claim 2, wherein, The traditional Chinese medicine composition is made from the following raw materials by weight: 30 parts forsythia, 30 parts honeysuckle, 30 parts mulberry leaf, 30 parts scrophularia, 9 parts ophiopogon japonicus and 6 parts licorice.

4. A pharmaceutical preparation, wherein, The pharmaceutical preparation comprises the traditional Chinese medicine composition or extract thereof as described in any one of claims 1-3.

5. The pharmaceutical preparation according to claim 4, wherein, The extract is an aqueous or alcoholic extract of the traditional Chinese medicine composition.

6. The pharmaceutical preparation according to claim 4, wherein, The pharmaceutical preparation also contains pharmaceutically acceptable excipients.

7. The pharmaceutical preparation according to claim 6, wherein, The excipients are selected from one or more of the following pharmaceutically acceptable solvents, solubilizers, cosolvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, flavoring agents, preservatives, suspending agents, coating materials, integrators, penetration enhancers, pH adjusters, buffers, plasticizers, surfactants, thickeners, inclusion agents, humectants, flocculants and anti-flocculation agents, filter aids, release inhibitors, polymeric framework materials, and film-forming materials.

8. The pharmaceutical preparation according to claim 4, wherein, The dosage form of the pharmaceutical preparation is tablets, capsules, powders, mixtures, pills, granules, oral liquids, syrups, decoctions, suppositories, gels, sprays, or injections.

9. Use of the traditional Chinese medicine composition of any one of claims 1-3 or the pharmaceutical preparation of any one of claims 4-8 in the preparation of a medicament for treating and / or preventing acute lung injury.

Images